Bhatia Jagriti, Gamad Nanda, Bharti Saurabh, Arya Dharamvir Singh
Jagriti Bhatia, Nanda Gamad, Saurabh Bharti, Dharamvir Singh Arya, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-110029, India.
World J Diabetes. 2014 Jun 15;5(3):399-406. doi: 10.4239/wjd.v5.i3.399.
Canagliflozin (CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter (SGLT) inhibitors, which got approval by food and drug administration. It has insulin independent action by blocking the transporter protein SGLT2 in the kidneys, resulting in urinary glucose excretion and reduction in blood glucose levels. In clinical trials, CFZ significantly decreased HbA1c level when administered either as monotherapy or as combined therapy with other anti-diabetic drugs. Intriguingly, it showed additional benefits like weight reduction and lowering of blood pressure. The commonly observed side effects were urinary and genital infections. It has exhibited favorable pharmacokinetic and pharmacodynamic profiles even in patients with renal and hepatic damage. Hence, this review purports to outline CFZ as a newer beneficial drug for type 2 diabetes mellitus.
卡格列净（CFZ）是一类新型降糖药物——钠-葡萄糖协同转运蛋白（SGLT）抑制剂中的一员，已获食品药品监督管理局批准。它通过阻断肾脏中的转运蛋白SGLT2发挥不依赖胰岛素的作用，导致尿糖排泄并降低血糖水平。在临床试验中，卡格列净无论是单药治疗还是与其他抗糖尿病药物联合治疗，均能显著降低糖化血红蛋白（HbA1c）水平。有趣的是，它还具有减轻体重和降低血压等额外益处。常见的副作用是泌尿系统和生殖器感染。即使在有肾损伤和肝损伤的患者中，它也表现出良好的药代动力学和药效学特征。因此，本综述旨在概述卡格列净作为一种治疗2型糖尿病的新型有益药物。
